Core Viewpoint - Abivax reported its full-year financial results for 2024, highlighting significant clinical progress and a strong cash position that supports its ongoing clinical trials and operational needs [2][3]. Financial Highlights - Total operating income for FY 2024 was EUR 12.5 million, an increase of EUR 7.9 million from EUR 4.6 million in FY 2023 [5]. - Research and Development (R&D) costs rose to EUR 146.5 million, up EUR 43.3 million from EUR 103.2 million in the previous year, primarily due to increased expenses related to the Phase 3 clinical trials for obefazimod [5][8]. - The net loss for the period was EUR 176.2 million, compared to EUR 147.8 million in FY 2023, reflecting higher operational expenditures [5][8]. - The cash balance as of December 31, 2024, was EUR 144.2 million, down from EUR 261.0 million in 2023, providing a cash runway into Q4 2025 [6][9]. Upcoming Milestones - Full enrollment in the Phase 3 ABTECT trial for obefazimod is expected in Q2 2025, with top-line results anticipated in Q3 2025 [6][7]. - Completion of the 44-week maintenance trial is projected for Q2 2026, with top-line results expected in the same quarter [7]. Operational Insights - The total number of employees increased to 69 as of December 31, 2024, from 61 in the previous year, indicating organizational growth [8]. - General and Administrative (G&A) expenses rose to EUR 32.9 million, up EUR 10.5 million from EUR 22.4 million in 2023, driven by increased headcount and legal fees associated with being a dual-listed company [8][12].
Abivax Announces Full Year 2024 Financial Results